1.07

3.88% 0.04

Neurosense Therapeutics Ltd (NRSN)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$1.03

Offen:

$1.02

24-Stunden-Volumen:

145.52K

Relative Volume:

1.06

Marktkapitalisierung:

$23.48M

Einnahmen:

Nettoeinkommen (Verlust:

$-13.76M

KGV:

-1.1505

EPS:

-0.93

Netto-Cashflow:

1W Leistung:

+9.33%

1M Leistung:

+8.08%

6M Leistung:

-14.40%

1J Leistung:

-19.55%

1-Tages-Spanne:

$1.02

$1.09

1-Wochen-Bereich:

$0.93

$1.09

52-Wochen-Spanne:

$0.512

$1.50

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Firmenname

Neurosense Therapeutics Ltd

Sektor

Healthcare (1150)

Branche

Biotechnology (676)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-31

Neueste SEC-Einreichungen

NRSN's Discussions on Twitter

Vergleichen Sie NRSN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRSN Neurosense Therapeutics Ltd	1.07	23.48M	0	-13.76M	0	-0.93
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten

Apr 30, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World

Apr 30, 2025

Apr 24, 2025

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks

Apr 24, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow

Apr 24, 2025

Apr 23, 2025

Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World

Apr 23, 2025

Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025

Apr 09, 2025

Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com

Apr 09, 2025

Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan

Apr 09, 2025

Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks

Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN

Apr 08, 2025

Apr 07, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - Quantisnow

Apr 07, 2025

Regulatory T-cells (Tregs) Market to Observe Significant Growth by 2034 Owing to the Development in 12+ Indications with Severe and Refractory Patients as the Treatment Addressable Population | DelveInsight - PR Newswire

Apr 07, 2025

Apr 04, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN

Apr 04, 2025

Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan

Apr 04, 2025

Mar 31, 2025

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com

Mar 31, 2025

Mar 27, 2025

NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks

Mar 27, 2025

Mar 25, 2025

Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com

Mar 25, 2025

Mar 24, 2025

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire

Mar 24, 2025

Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com

Mar 24, 2025

Mar 22, 2025

NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World

Mar 22, 2025

Mar 21, 2025

NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge

Mar 21, 2025

Mar 20, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire

Mar 20, 2025

Mar 19, 2025

NeuroSense Advances PrimeC Commercialization in Canada - TipRanks

Mar 19, 2025

Mar 17, 2025

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com

Mar 17, 2025

Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan

Mar 17, 2025

Feb 27, 2025

The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury

Feb 27, 2025

Feb 19, 2025

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks

Feb 19, 2025

Jan 14, 2025

NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks

Jan 14, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World

Jan 14, 2025

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost - Investing.com

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria

Jan 06, 2025

NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks

Jan 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com

Jan 06, 2025

Jan 03, 2025

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com

Jan 03, 2025

Dec 31, 2024

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com

Dec 31, 2024

Dec 28, 2024

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com

Dec 28, 2024

Dec 25, 2024